A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer.

Abedian Kalkhoran, Hanieh; Zwaveling, Juliëtte; Storm, Bert N; van Laar, Sylvia A; Portielje, Johanneke Ea; Codrington, Henk; Luijten, Dieuwke; Brocken, Pepijn; Smit, Egbert F; Visser, Loes E

Abedian Kalkhoran, Hanieh; Zwaveling, Juliëtte; Storm, Bert N; van Laar, Sylvia A; Portielje, Johanneke Ea; Codrington, Henk; Luijten, Dieuwke; Brocken, Pepijn; Smit, Egbert F; Visser, Loes E.

Afiliação

Abedian Kalkhoran H; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands. h.abedian_kalkhoran@lumc.nl.
Zwaveling J; Department of Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands. h.abedian_kalkhoran@lumc.nl.
Storm BN; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
van Laar SA; Department of Pharmacy, Haga Teaching Hospital, The Hague, The Netherlands.
Portielje JE; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, Leiden, The Netherlands.
Codrington H; Department of Internal Medicine - Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands.
Luijten D; Department of Pulmonary Diseases - Pulmonic Oncology, Haga Teaching Hospital, The Hague, The Netherlands.
Brocken P; Department of Pulmonary Diseases - Pulmonic Oncology, Haga Teaching Hospital, The Hague, The Netherlands.
Smit EF; Department of Pulmonary Diseases - Pulmonic Oncology, Haga Teaching Hospital, The Hague, The Netherlands.
Visser LE; Department of Pulmonary Disease, Leiden University Medical Centre, Leiden, The Netherlands.

BMC Cancer ; 23(1): 247, 2023 Mar 14.

Article em En | MEDLINE | ID: mdl-36918817

Assuntos

Antineoplásicos Imunológicos; Carcinoma Pulmonar de Células não Pequenas; Neoplasias Pulmonares; Pessoa de Meia-Idade; Humanos; Idoso; Inibidores de Checkpoint Imunológico/efeitos adversos; Receptor de Morte Celular Programada 1/uso terapêutico; Estudos Retrospectivos; Antineoplásicos Imunológicos/efeitos adversos

Palavras-chave

Anti-PD-(L)1 therapy; Elderly; Immune checkpoint inhibitor (ICI); Non-small cell lung cancer (NSCLC); Real-world

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Antineoplásicos Imunológicos / Neoplasias Pulmonares Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Humans / Middle aged Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google